Ole Bitsch-Jensen

Asiros A/S manufactures bioactive based food ingredients and formulation. Its products include BerryShield berry powders used to manufacture berry powders and MitoActive products are based on the discovery of a bioactive compound in certain varieties of red- and blackcurrants. The comapny was founded in 2007 and is headquartered in Copenhagen, Denmark.

Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark.

SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark.

Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark.

OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark.

Pharma 2100 ApS engages in the research and development of pharmaceutical products. It conducts research on medical drugs to obtain patents and possible productions of these drugs. The company was founded on January 1, 2002 and is headquartered in Vanløse, Denmark.

CytoTrack ApS engages in the provision of medical scanners for rare cell detection systems. Its products include CytoTrack CT11 scanner, CytoDisk and CytoCover, and CytoTrack reagent kit. The company was founded by Christian Caspersen, Tom Hede Markussen and Lars Ulrik Nielsen in 2004 and is headquartered in Lyngby, Denmark.

Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.

FluimediX ApS provides diagnostic system capable of deoxyribonucleic acid based species determination. Its product, called NanoCycler, delivers an identification of the presence of patogen species, based on their unique DNA 'fingerprint'. The firm markets its product for the use of the dairy production industry. It also collaborates with others in the fields of engineering, microtechnology, and surface analysis. The company was founded by Tomas Ussing in 2003 and is headquartered in Taastrup, Denmark.